D.A. Davidson & Co. Vertex Pharmaceuticals Inc Transaction History

D.A. Davidson & Co.

$12 Billion
Q3 2024

A detailed history of D.A. Davidson & Co. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, D.A. Davidson & Co. holds 5,475 shares of VRTX stock, worth $2.24 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

5,475

Previous 4,864 12.56%

Holding current value

$2.24 Million

Previous $2.28 Million 11.72%

% of portfolio

0.02%

Previous 0.02%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$460.0 - $505.78 $281,060 - $309,031	611 Added 12.56%	5,475 $2.55 Million
Q2 2024 Jul 31, 2024	SELL	$392.81 - $485.53 $8,641 - $10,681	-22 Reduced 0.45%	4,864 $2.28 Million
Q1 2024 May 13, 2024	BUY	$407.69 - $446.08 $989,463 - $1.08 Million	2,427 Added 98.7%	4,886 $2.04 Million
Q4 2023 Feb 09, 2024	SELL	$343.0 - $410.68 $310,072 - $371,254	-904 Reduced 26.88%	2,459 $1 Million
Q3 2023 Nov 08, 2023	BUY	$338.18 - $362.46 $37,199 - $39,870	110 Added 3.38%	3,363 $1.17 Million
Q2 2023 Aug 10, 2023	SELL	$314.42 - $351.91 $163,812 - $183,345	-521 Reduced 13.8%	3,253 $1.14 Million
Q1 2023 Apr 25, 2023	SELL	$283.23 - $323.1 $160,591 - $183,197	-567 Reduced 13.06%	3,774 $1.19 Million
Q4 2022 Feb 03, 2023	BUY	$285.76 - $321.48 $640,102 - $720,115	2,240 Added 106.62%	4,341 $1.25 Million
Q3 2022 Nov 07, 2022	SELL	$273.83 - $305.53 $38,610 - $43,079	-141 Reduced 6.29%	2,101 $608,000
Q2 2022 Jul 28, 2022	BUY	$234.96 - $292.55 $14,332 - $17,845	61 Added 2.8%	2,242 $632,000
Q1 2022 May 12, 2022	BUY	$221.42 - $260.97 $209,906 - $247,399	948 Added 76.89%	2,181 $569,000
Q4 2021 Jan 31, 2022	SELL	$177.01 - $223.45 $531 - $670	-3 Reduced 0.24%	1,233 $271,000
Q3 2021 Nov 15, 2021	BUY	$181.39 - $202.99 $224,198 - $250,895	1,236 New	1,236 $224,000
Q2 2021 Aug 10, 2021	SELL	$187.49 - $221.1 $174,740 - $206,065	-932 Closed	0 $0
Q1 2021 May 07, 2021	BUY	$207.02 - $241.31 $192,942 - $224,900	932 New	932 $200,000
Q4 2020 Feb 10, 2021	SELL	$207.01 - $276.09 $174,095 - $232,191	-841 Closed	0 $0
Q3 2020 Nov 02, 2020	BUY	$255.65 - $303.1 $17,895 - $21,217	70 Added 9.08%	841 $229,000
Q2 2020 Aug 10, 2020	BUY	$225.48 - $295.8 $173,845 - $228,061	771 New	771 $224,000
Q2 2019 Aug 13, 2019	SELL	$164.61 - $190.37 $3.57 Million - $4.13 Million	-21,676 Closed	0 $0
Q1 2019 May 13, 2019	SELL	$163.73 - $194.7 $102,167 - $121,492	-624 Reduced 2.8%	21,676 $3.99 Million
Q4 2018 Jan 29, 2019	SELL	$151.91 - $192.21 $35,395 - $44,784	-233 Reduced 1.03%	22,300 $3.7 Million
Q3 2018 Nov 13, 2018	SELL	$167.73 - $192.74 $34,552 - $39,704	-206 Reduced 0.91%	22,533 $4.34 Million
Q2 2018 Aug 02, 2018	SELL	$145.72 - $169.96 $97,923 - $114,213	-672 Reduced 2.87%	22,739 $3.87 Million
Q1 2018 May 04, 2018	SELL	$151.6 - $177.13 $45,631 - $53,316	-301 Reduced 1.27%	23,411 $3.82 Million
Q4 2017 Feb 08, 2018	SELL	$137.28 - $155.55 $182,033 - $206,259	-1,326 Reduced 5.3%	23,712 $3.55 Million
Q3 2017 Nov 08, 2017	BUY	$148.13 - $162.24 $19,701 - $21,577	133 Added 0.53%	25,038 $3.81 Million
Q2 2017 Aug 11, 2017	BUY	N/A	24,905	24,905 $0

Others Institutions Holding VRTX

# of Institutions

1,724

Shares Held

221M

Call Options Held

1.58M

Put Options Held

1.36M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $105B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D.A. Davidson & Co., based on Form 13F filings with the SEC.

News

Stay updated on D.A. Davidson & Co. with notifications on news.

Account